Pediatric cirrhotic cardiomyopathy: Impact on liver transplant outcomes

Norman Junge1, Claudia Junge2, Julian Schröder1

  • 1Paediatric Gastroenterology and Hepatology.

Insights

Cirrhotic cardiomyopathy in pediatric liver transplant candidates causes mild, reversible cardiac changes, particularly with cholestasis. These changes can affect transplant care but do not impact survival.

Area of Science:

  • Cardiology
  • Hepatology
  • Pediatric Gastroenterology

Background:

  • Cirrhotic cardiomyopathy (CCM) is common in adults awaiting liver transplantation.
  • Data on cardiac changes in pediatric liver transplant (pLT) candidates, especially comparing cirrhotic to non-cirrhotic liver disease, is limited.

Purpose of the Study:

  • To evaluate cardiac changes in pediatric liver transplant candidates with cirrhotic liver disease.
  • To compare cardiac findings between cirrhotic and non-cirrhotic pediatric liver disease.
  • To assess the reversibility of cardiac changes after pLT.

Main Methods:

  • Retrospective analysis of 198 pediatric liver transplant candidates (median age 4.1 years).
  • Echocardiography and 12-lead electrocardiogram assessments before and 12 months after pLT.
  • Correlation of cardiac findings with liver fibrosis and cholestasis stages.

Main Results:

  • Cirrhotic patients showed significantly higher left ventricular end-diastolic diameter (LVIDd) z score, left ventricular mass z score, and mass index compared to non-cirrhotic patients.
  • Pathological LVIDd z scores were more frequent in cirrhotic patients and associated with cholestasis.
  • All cardiac changes, including pathological LVIDd z scores, were reversible 1 year after pLT and correlated with longer ICU stay but not survival.
  • Prolonged QTc time was not associated with liver cirrhosis in this cohort.

Conclusions:

  • Pediatric liver transplant candidates with cirrhotic liver disease exhibit frequent, mild, and reversible cardiac changes, linked to cholestasis.
  • These CCM-associated changes can influence peritransplant care and hospitalization duration.
  • Further prospective studies are needed to investigate QTc prolongation factors and potential benefits of ursodeoxycholic acid.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
589
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
526
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
587
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
470
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
619
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
365